GLP1RAs in Clinical Practice: Therapeutic Advances and Safety Perspectives – American College of Cardiology
Health care professionals should explore the use of glucagon-like peptide-1 receptor agonists (GLP1RAs) for cardiovascular risk reduction and their broader impacts on cardiometabolic health beyond diabetes mellitus management, guided by the latest clinical trial findings and guidelines. Clinicians should be vigilant for gastrointestinal tract adverse effects in patients using GLP1RAs, advising gradual dose escalation and employing toolkits to improve tolerability. Glucagon-like peptide-1 is an incretin